Frontier Capital Management Co. LLC Has $22.40 Million Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Frontier Capital Management Co. LLC cut its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 243,664 shares of the medical device company's stock after selling 3,172 shares during the period. Frontier Capital Management Co. LLC owned approximately 0.12% of Cooper Companies worth $22,400,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Byrne Asset Management LLC bought a new position in Cooper Companies during the fourth quarter worth about $33,000. OFI Invest Asset Management bought a new position in Cooper Companies during the fourth quarter worth about $34,000. New Age Alpha Advisors LLC bought a new position in Cooper Companies during the fourth quarter worth about $38,000. Covestor Ltd lifted its holdings in Cooper Companies by 35.5% during the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company's stock worth $42,000 after acquiring an additional 120 shares in the last quarter. Finally, West Financial Advisors LLC acquired a new stake in shares of Cooper Companies in the 4th quarter valued at about $49,000. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Stock Down 0.8%

Shares of NASDAQ:COO traded down $0.65 during midday trading on Friday, reaching $82.27. The company had a trading volume of 1,265,544 shares, compared to its average volume of 1,447,855. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The business's 50 day moving average price is $80.54 and its 200 day moving average price is $90.81. The stock has a market cap of $16.45 billion, a PE ratio of 42.19, a P/E/G ratio of 2.25 and a beta of 1.08. The Cooper Companies, Inc. has a 1-year low of $69.81 and a 1-year high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $964.70 million for the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. Research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

COO has been the topic of several recent research reports. Citigroup dropped their price target on Cooper Companies from $115.00 to $110.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Stifel Nicolaus dropped their price target on Cooper Companies from $115.00 to $105.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. BNP Paribas raised Cooper Companies to a "hold" rating in a research note on Thursday, March 13th. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research note on Friday, March 7th. Finally, Robert W. Baird dropped their price target on Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a research note on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $110.25.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.